CAJ | 학술논문

目的观察精确腹腔热灌注化疗治疗晚期胰腺癌的临床疗效.方法对本院收治的36例晚期胰腺癌患者进行回顾性分析,治疗组18例进行腹腔热灌注化疗联合放化疗,对照组18例进行放化疗.比较两组患者近期疗效、Karnofsky功能状态评分、不良反应发生率及生存时间之间的差异.结果治疗组患者的近期肿瘤减小总有效率为66.67％ (12/18),对照组患者的近期肿瘤减小总有效率为27.78％(5/18),两组治疗有效率比较差异有统计学意义(P＜0.05);治疗后治疗组患者KPS评分升高幅度明显大于对照组(P＜0.05);治疗组与对照组患者不良反应率比较差异无统计学意义(P＞0.05);治疗组患者中位总生存时间为11个月(7 ～31个月),对照组中位总生存时间为7个月(4～18个月),治疗组生存时间显著延长(P＜0.05).结论腹腔热灌注化疗治疗晚期胰腺癌可显著改善患者生活质量,延长生存期,且不良反应小,值得临床推广应用.
목적 관찰정학복강열관주화료치료만기이선암적림상료효.방법 대본원수치적36례만기이선암환자진행회고성분석,치료조18례진행복강열관주화료연합방화료,대조조18례진행방화료.비교량조환자근기료효、Karnofsky공능상태평분、불량반응발생솔급생존시간지간적차이.결과 치료조환자적근기종류감소총유효솔위66.67％ (12/18),대조조환자적근기종류감소총유효솔위27.78％(5/18),량조치료유효솔비교차이유통계학의의(P＜0.05);치료후치료조환자KPS평분승고폭도명현대우대조조(P＜0.05);치료조여대조조환자불량반응솔비교차이무통계학의의(P＞0.05);치료조환자중위총생존시간위11개월(7 ～31개월),대조조중위총생존시간위7개월(4～18개월),치료조생존시간현저연장(P＜0.05).결론 복강열관주화료치료만기이선암가현저개선환자생활질량,연장생존기,차불량반응소,치득림상추엄응용.
Objective To investigate the efficacy of precise hyperthermic intraperitoneal perfusion chemotherapy (HIPEC) in the treatment of advanced pancreatic cancer.Methods Thirty-six patients with advanced pancreatic cancer were analyzed retrospectively.Eighteen patients who received HIPEC combined with radiotherapy and chemotherapy were assigned as the treatment group and the other 18 patients who received chemotherapy and radiotherapy were assigned as the control group.Recent curative efficacy,Karnofsky Performance Status (KPS) score,postoperative complications and survivals between the two groups were analyzed,respectively.Results Significant differences were found between two groups in total short-term effective rate (P ＜ 0.05).The total short-term effective rate of treatment group and control group were 66.67％ (12/18) and 27.78％ (5/18),respectively.The increment of KPS score of treatment group was significantly higher than that of control group (P ＜ 0.05).There was no significant difference between two groups in postoperative complications (P ＞ 0.05).The median overall survival time (OS) of treatment group was 11 months (7 ～ 31 months),and the median OS of control group was 7 months (4 ～ 18 months).The survival of the treatment group was longer than the control group (P ＜ 0.05).Conclusions HIPEC treatment improved significantly the survival and life quality of advanced pancreatic cancer patients.With acceptable morbidity and mortality rates,HIPEC regime was an effective treatment modality for patients with advanced pancreatic cancer.